{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056935","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.960165+00:00","generated_at":"2026-06-02T07:08:50.476664+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tyra Biosciences Q1 net loss $18.2M; cash $382.5M; TYRA-300 on track for 2H24 milestones","bullets":["Net loss of $18.2M in Q1 2024 vs $11.9M in Q1 2023; R&D expenses $17.2M.","Cash, equivalents, and marketable securities of $382.5M as of March 31, 2024; funding through at least 2026.","Closed $200M private placement in Feb 2024.","TYRA-300 on track for ACH IND submission and initial SURF301 results in 2H24.","Appointed Susan Moran, M.D. and S. Michael Rothenberg, M.D., Ph.D. to board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056935","json":"https://secwatch.observer/filing/0000950170-24-056935.json","markdown":"https://secwatch.observer/filing/0000950170-24-056935.md","text":"https://secwatch.observer/filing/0000950170-24-056935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024056935/0000950170-24-056935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024056935/tyra-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:08:50.476664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1937cc58038b1639d3ddb1fca8a9cb7cdef99cad","claim":"Tyra Biosciences, Inc. reported the quarter ended March 31, 2024 results: net income First quarter 2024 net loss was $18.2 million.","evidence_excerpt":"On May 9, 2024, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024056935/0000950170-24-056935-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"First quarter 2024 net loss was $18.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}